Pimavanserin: First Global Approval.

Article Details

Citation
Copy to clipboard

Markham A

Pimavanserin: First Global Approval.

Drugs. 2016 Jul;76(10):1053-7. doi: 10.1007/s40265-016-0597-9.

PubMed ID
27262680 [ View in PubMed
]
Abstract

Pimavanserin (Nuplazid) is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist and antagonist developed by ACADIA Pharmaceuticals that has been approved in the US as a treatment for patients with hallucinations and delusions associated with Parkinson's disease psychosis. Up to 60 % of patients with Parkinson's disease may develop Parkinson's disease psychosis, which is associated with increased morbidity and mortality and has few treatment options. This article summarizes the milestones in the development of pimavanserin leading to this first approval for the treatment of hallucinations and delusions in patients with Parkinson's disease psychosis.

DrugBank Data that Cites this Article

Drugs